BioChemics, Inc. Announces Collaboration Agreement with Unilever

DANVERS, Mass.--(Business Wire)--
BioChemics, Inc. a company "enhancing drug delivery through biophysical
modulation," is pleased to announce the signing of a research collaboration
agreement with Unilever, one of the world`s largest consumer goods companies, to
utilize BioChemics` proprietary topical delivery technology for the delivery of
Unilever`s compounds.

"We are delighted to be working with Unilever to evaluate the broader
applications of our technology for their products," said President and Chief
Executive Officer John J. Masiz, Esq.

"In addition to our other ongoing collaborations, this agreement further
validates the impact for our proprietary topical technology, making us
attractive to a wide variety of partners to develop well-differentiated,
cost-effective products for consumers."

About BioChemics, Inc.

BioChemics is a pharmaceutical company that has developed a novel, transdermal
drug delivery system for the first time that may allow almost any drug to be
efficiently delivered through the skin. The transdermal technology, called VALE
(Vaso-active Lipid Encapsulated), may allow a substantial portion of the
pharmacopeia to be re-engineered, turning oral drugs into transdermals that are
safer (no gastro-intestinal problems), cheaper and potentially faster acting
(applied directly to the treated area) than oral equivalents. The company's
focus is on multi-billion dollar market opportunities currently underserved by
existing therapies. The company's two lead clinical products focus on treating
diabetic peripheral neuropathy and osteoarthritis. Founded in 1989, the Company
is headquartered in Danvers, Massachusetts. Additional information is available
at http://www.biochemics.com.

BioChemics, Inc.
Laura Stephens, 978-750-0090 ext.17
Business Development
jmasiz@biochemics.com

Copyright Business Wire 2009